18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model.
EJNMMI Res
; 8(1): 53, 2018 Jun 18.
Article
en En
| MEDLINE
| ID: mdl-29916085
ABSTRACT
BACKGROUND:
Quantitative imaging can facilitate patient stratification in clinical trials. The hypoxia-activated prodrug evofosfamide recently failed a phase III trial in pancreatic cancer. However, the study did not attempt to select for patients with hypoxic tumors. We tested the ability of 18F-fluoromisonidazole to predict evofosfamide uptake in an orthotopic xenograft model (BxPC3).METHODS:
Two forms of evofosfamide were used (1) labeled on the active moiety (3H) and (2) on the hypoxia targeting nitroimidazole group (14C). Tumor uptake of evofosfamide and 18F-fluoromisonidazole was counted ex vivo. Autoradiography of 14C and 18F coupled with pimonidazole immunohistochemistry revealed the spatial distributions of prodrug, radiotracer, and hypoxia.RESULTS:
There was significant individual variation in 18F-fluoromisonidazole uptake, and a significant correlation between normalized 18F-fluoromisonidazole and both 3H-labeled and 14C-labeled evofosfamide. 18F-fluoromisonidazole and 14C-evofosfamide both localized in hypoxic regions as identified by pimonidazole.CONCLUSION:
18F-fluoromisonidazole predicts evofosfamide uptake in a preclinical pancreatic tumor model.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
EJNMMI Res
Año:
2018
Tipo del documento:
Article
País de afiliación:
Estados Unidos